Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New ECT technique aims to treat severe depression with fewer memory problems

NCT ID NCT05402657

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way of giving electroconvulsive therapy (ECT) for severe depression. The goal was to see if a different electrode placement on the head could reduce memory loss while still effectively treating depression. 156 adults with severe depression took part, receiving either the standard or the new ECT placement over about 4 weeks, followed by 24 weeks of follow-up. The study compared how well each type worked and how it affected memory.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

156 people

The number who actually took part.

Started

Mar 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * DSM-5 diagnosis\* of major depressive episode (unipolar or bipolar) * HRSD-17 score ≥ 17 at Screening * At least 18 years old * Able to tolerate washout of prohibited medications and restriction on benzodiazepine dosage, as determined by patient's own treating psychiatrist. * ECT indicated for treatment of depression, as determined by own treating referring psychiatrist and confirmed by research evaluations (e.g., diagnosis of depression) * Willing and able to participate in research and comply with study requirements * Sufficient proficiency in spoken English to ensure validity of neuropsychological testing (e.g., worked or studied in an English-speaking context or equivalent) Exclusion Criteria: * History of schizophrenia, schizoaffective disorder, other \[non-mood disorder\] psychosis, or rapid cycling bipolar disorder (DSM-5 diagnoses\*) * Current manic episode, hypomanic episode, or major depressive episode with mixed features (DSM-5 diagnoses\*) * Alcohol or substance use disorder (other than caffeine or nicotine) present in the past month, or is likely to be present during the 24-week study period as determined by study physician evaluation * Diagnosis of amnestic disorder, dementia, delirium, or epilepsy, as determined by study physician evaluation and medical history * Central nervous system disease or brain injury that has resulted in significant cognitive impact, as determined by study physician evaluation and medical history * Serious or unstable medical condition, as determined by study physician evaluation and medical history * If female of childbearing potential: a) pregnancy as determined by pregnancy urine screen * Completed an acute course of ECT during the past 2 months, as determined by treatment history * Received any ECT during the past 2 weeks * Failed an adequate course of ECT (i.e., 8 ECT treatments ) in the current depressive episode * Patients who are prisoners, and those who lack capacity to make medical decisions (as judged by their own treating psychiatrist) * Currently enrolled in another interventional clinical trial * Currently using another investigational device or product * DSM-5 psychiatric diagnoses will be assessed and confirmed using the Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) Version 7.0.2 for DSM-5, administered by research team members.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive episode are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Gold Coast University Hospital (GCUH)

    Gold Coast, Queensland, 4215, Australia

  • Medical College of Georgia, Augusta University

    Augusta, Georgia, 30912, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Ramsay Clinic Albert Road

    Melbourne, Victoria, 3004, Australia

  • Ramsay Clinic Lakeside

    Warners Bay, New South Wales, 2282, Australia

  • Ramsay Clinic Northside

    Sydney, New South Wales, 2065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.